Triple-negative breast cancer: investigating potential molecular therapeutic target

Papa, Anselmo; Caruso, Davide; Tomao, Silverio; Rossi, Luigi; Zaccarelli, Eleonora; Tomao, Federica

doi:10.1517/14728222.2014.970176

Cited by 50 publications

(36 citation statements)

References 231 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in ERα-negative breast cancer tissue and cells, ERβ exhibits pro-growth and pro-survival activity [131]. Moreover, ERβ1 (wild-type ERβ) coexists with four ERβ variants (designated ERβ2 to ERβ5) that complicate elucidation of their physiological role and involvement in ER carcinogenesis [132]. ERβ1 is the one fully functional variant.…”

Section: The Role Of Ers In Breast Cancersmentioning

confidence: 99%

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Song

Sinha

et al. 2019

Oncogene

View full text Add to dashboard Cite

show abstract

Section: The Role Of Ers In Breast Cancersmentioning

confidence: 99%

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Song

Sinha

et al. 2019

Oncogene

View full text Add to dashboard Cite

show abstract

“…[2] TNBC is a heterogeneous group of tumors characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2/Neu (HER2), and this malignancy has been found to be often, but not always, a basal-like breast cancer. [3] Because it cannot be treated with current endocrine therapies and exhibits an aggressive nature, TNBC has been regarded as being associated with one of the worst prognoses of all breast cancer subtypes. [2,4] …”

Section: Introductionmentioning

confidence: 99%

MicroRNAs in the prognosis of triple-negative breast cancer

Mao

Shi

et al. 2017

Medicine

View full text Add to dashboard Cite

Background:Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by their aggressive nature and poor associated survival. MicroRNAs (miRs) have been found to play an important role in the occurrence and development of human cancers, but their role in the prognosis of TNBC patients remains unclear. We performed a meta-analysis to explore the prognostic value of miRs in TNBC.Methods:We systematically searched the PubMed, Embase, and Web of Science databases to identify eligible studies. A meta-analysis was performed to estimate the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for the associations between levels of miR expression (predictive factors) and overall survival (OS) and disease-free survival (DFS) (outcomes) in patients with TNBC.Results:After performing the literature search and review, 21 relevant studies including 2510 subjects were identified. Six miRs (miR-155, miR-21, miR-27a/b, miR-374a/b, miR-210, and miR-454) were assessed in the meta-analysis. Decreased expression of miR-155 was associated with reduced OS (adjusted HR = 0.58, 95% CI: 0.34–0.99; crude HR = 0.67, 95% CI: 0.58–0.79). High miR-21 expression was also predictive of reduced OS (crude HR = 2.50, 95% CI: 1.56–4.01). We found that elevated levels of miR-27a/b, miR-210, and miR-454 expression were associated with shorter OS, while the levels of miR-454 and miR-374a/b expression were associated with DFS.Conclusions:Specific miRs could serve as potential prognostic biomarkers in TNBC. Due to the limited research available, the clinical application of these findings has yet to be verified.

show abstract

“…[3][4][5][6][7] However, the biologic heterogeneity of tumors remains a challenge, especially for triple negative (TN) breast tumors, which present the poorest prognosis among different subtypes and have no standard targeted therapies. [8][9][10][11] Efficient prognosis and treatment must consider specific molecular and cellular features of the disease, thus, understanding critical cellular pathways in tumor biology is of great importance. Exploring DNA damage response (DDR) pathways has been a promising strategy in the development of specific anti-tumoral agents; a remarkable example is the sensitivity of BRCA1/2 deficient cells to Poly (ADP ribose) Polymerase (PARP) inhibitors.…”

Section: Introductionmentioning

confidence: 99%

DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis

Gregoriis

Ramos

Fernandes

et al. 2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

Despite remarkable advances in diagnosis, prognosis and treatment, advanced or recurrent breast tumors have limited therapeutic approaches. Many treatment strategies try to explore the limitations of DNA damage response (DDR) in tumor cells to selectively eliminate them. BRCT (BRCA1 C-terminal) domains are present in a superfamily of proteins involved in cell cycle checkpoints and the DDR. Tandem BRCT domains (tBRCT) represent a distinct class of these domains. We investigated the expression profile of 7 tBRCT genes (BARD1, BRCA1, LIG4, ECT2, MDC1, PAXIP1/PTIP and TP53BP1) in breast cancer specimens and observed a high correlation between PAXIP1 and TP53BP1 gene expression in tumor samples. Tumors with worse prognosis (tumor grade 3 and triple negative) showed reduced expression of tBRCT genes, notably, PAXIP1 and TP53BP1. Survival analyses data indicated that tumor status of both genes may impact prognosis. PAXIP1 and 53BP1 protein levels followed gene expression results, i.e., are intrinsically correlated, and also reduced in more advanced tumors. Evaluation of both genes in triple negative breast tumor samples which were characterized for their BRCA1 status showed that PAXIP1 is overexpressed in BRCA1 mutant tumors. Taken together our findings indicate that PAXIP1 status correlates with breast cancer staging, in a manner similar to what has been characterized for TP53BP1.

show abstract

Triple-negative breast cancer: investigating potential molecular therapeutic target

Cited by 50 publications

References 231 publications

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1

MicroRNAs in the prognosis of triple-negative breast cancer

DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis

Contact Info

Product

Resources

About